Moderna (NASDAQ:MRNA) Shares Up 7.7% - What's Next?

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) was up 7.7% during mid-day trading on Friday . The stock traded as high as $36.20 and last traded at $36.93. Approximately 2,467,616 shares traded hands during trading, a decline of 80% from the average daily volume of 12,320,777 shares. The stock had previously closed at $34.30.

Analyst Ratings Changes

Several analysts have recently issued reports on MRNA shares. Wolfe Research assumed coverage on shares of Moderna in a research report on Friday, November 15th. They set an "underperform" rating and a $40.00 target price on the stock. The Goldman Sachs Group downgraded shares of Moderna from a "buy" rating to a "neutral" rating and cut their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Leerink Partners cut their price target on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a report on Thursday, January 16th. Morgan Stanley cut their price target on shares of Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a report on Wednesday, January 15th. Finally, Hsbc Global Res upgraded shares of Moderna from a "hold" rating to a "strong-buy" rating in a report on Monday, November 18th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $60.63.

Remove Ads

Moderna Stock Up 3.8 %

The stock's 50 day moving average price is $36.60 and its 200-day moving average price is $49.03. The stock has a market capitalization of $13.74 billion, a P/E ratio of -3.84 and a beta of 1.86.

Institutional Investors Weigh In On Moderna

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Knuff & Co LLC lifted its position in Moderna by 5.4% during the third quarter. Knuff & Co LLC now owns 4,732 shares of the company's stock valued at $316,000 after acquiring an additional 244 shares during the last quarter. Stephens Inc. AR lifted its position in Moderna by 7.9% during the third quarter. Stephens Inc. AR now owns 3,334 shares of the company's stock valued at $223,000 after acquiring an additional 245 shares during the last quarter. Allworth Financial LP lifted its position in Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock valued at $73,000 after acquiring an additional 281 shares during the last quarter. Howard Capital Management Inc. lifted its position in Moderna by 3.1% during the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock valued at $416,000 after acquiring an additional 297 shares during the last quarter. Finally, Larson Financial Group LLC lifted its position in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company's stock valued at $61,000 after acquiring an additional 317 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.